Wegovy Tablets vs Mounjaro: Which Is Better for Weight Loss?

The UK weight-management market has changed significantly with the arrival of Wegovy tablets.

Wegovy has traditionally been associated with a once-weekly injection containing semaglutide. In June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved an oral version of Wegovy for weight loss and weight management in eligible adults in the UK. The tablet is taken once daily.

At the same time, Mounjaro has become one of the most widely discussed weight-management medicines available in the UK. It contains tirzepatide, a medicine that works on both GIP and GLP-1 receptors.

This has led to a new question for people considering treatment:

Is the Wegovy pill better than Mounjaro?

The answer depends on what you mean by "better".

If your priority is avoiding injections, the Wegovy tablet has an obvious advantage.

If your priority is the greatest average weight loss demonstrated in a direct trial against injectable semaglutide, tirzepatide has produced stronger results.

However, there is an important scientific distinction.

Mounjaro has not yet been directly compared with the new Wegovy tablet in a head-to-head clinical trial.

Therefore, it would be inaccurate to claim that Mounjaro has been proven to cause more weight loss than oral Wegovy.

Instead, we need to look at the evidence for each treatment separately and understand how the medicines differ.

What is the Wegovy tablet?

The Wegovy tablet contains semaglutide, a GLP-1 receptor agonist.

Semaglutide mimics the action of a naturally occurring hormone called glucagon-like peptide-1, or GLP-1.

GLP-1 is involved in appetite regulation and satiety. By activating GLP-1 receptors, semaglutide can help people feel fuller for longer, reduce hunger and decrease food intake.

The oral Wegovy formulation provides an alternative to injectable semaglutide.

This could be particularly useful for people who:

• Do not like needles
• Feel uncomfortable using injections
• Prefer taking medication by mouth
• Want a weight loss tablet rather than an injection
• Prefer daily oral medication
• Find tablets easier to incorporate into their routine

The MHRA authorised the Wegovy tablet in the UK on 11 June 2026 for eligible adults with obesity, or adults who are overweight and have at least one weight-related health condition. It is used alongside a reduced-calorie diet and increased physical activity.

What is Mounjaro?

Mounjaro contains tirzepatide.

Tirzepatide is different from semaglutide because it acts on two hormone pathways:

• GIP
• GLP-1

This makes tirzepatide a dual GIP and GLP-1 receptor agonist.

Mounjaro is administered once a week by injection and can be prescribed for eligible patients as part of a medically supervised weight-management programme.

The medicine can reduce appetite and food intake, helping patients achieve weight loss when combined with appropriate lifestyle measures.

You can learn more about weight loss injections such as Mounjaro and Wegovy in our detailed UK guide.

How do Wegovy tablets and Mounjaro work?

Although both medicines can help with weight loss, their mechanisms are not identical.

How Wegovy tablets work

Wegovy tablets contain semaglutide, which activates GLP-1 receptors.

GLP-1 is naturally released by the body following food intake and is involved in appetite regulation.

Semaglutide can help:

• Reduce hunger
• Increase feelings of fullness
• Reduce food intake
• Reduce cravings
• Support weight loss
• Support long-term weight management

The important point is that semaglutide does not simply "burn fat".

Its primary weight-management effect comes through changes in appetite regulation and food intake.

How Mounjaro works

Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors.

This dual mechanism affects pathways involved in appetite, satiety and metabolism.

The result can be substantial weight loss in appropriately selected patients.

Tirzepatide's dual mechanism is one reason researchers have investigated whether it could produce greater weight reduction than GLP-1-only medicines such as semaglutide.

Which causes more weight loss: Wegovy tablets or Mounjaro?

This is where the comparison needs some care.

The new Wegovy tablet has clinical trial evidence demonstrating significant weight loss.

In the OASIS 4 trial, 307 adults with overweight or obesity but without diabetes were randomly assigned to once-daily oral semaglutide 25 mg or placebo.

At week 64, the estimated mean change in body weight was:

13.6% with oral semaglutide compared with 2.2% with placebo.

The study also found that oral semaglutide significantly increased the proportion of participants achieving at least 5%, 10%, 15% and 20% weight loss.

These are meaningful results.

However, OASIS 4 was a placebo-controlled trial. It was not a direct comparison between the Wegovy tablet and Mounjaro.

What does the research say about Mounjaro vs Wegovy?

A separate clinical trial called SURMOUNT-5 directly compared tirzepatide with injectable semaglutide.

The study included adults with obesity who did not have type 2 diabetes.

After 72 weeks:

• Tirzepatide produced an average weight reduction of 20.2%
• Injectable semaglutide produced an average weight reduction of 13.7%

Tirzepatide was therefore superior to injectable semaglutide for weight reduction in this trial.

This is important evidence when considering Mounjaro vs Wegovy.

But it is crucial to understand that the trial used injectable semaglutide, not the newly authorised oral Wegovy formulation.

Therefore, the results cannot be used to claim that Mounjaro definitively produces more weight loss than Wegovy tablets.

So, is Mounjaro better than the Wegovy pill?

There is currently no simple yes-or-no answer.

Based on the available evidence:

Mounjaro has demonstrated greater average weight loss than injectable semaglutide in a direct head-to-head trial.

Oral semaglutide has demonstrated substantial weight loss compared with placebo.

But there has not been a direct trial comparing Mounjaro with oral Wegovy.

This distinction is particularly important as the Wegovy tablet is a relatively new option in the UK.

If future clinical trials directly compare oral semaglutide with tirzepatide, we will have a stronger basis for answering the question of which is more effective.

For now, treatment choice should be based on the available evidence alongside your individual clinical circumstances.

Wegovy tablets vs Mounjaro: which is easier to take?

For many people, this may be one of the most important differences.

Wegovy tablets

Wegovy tablets are taken once daily.

The biggest potential advantage is that there is no injection.

This may appeal to people who:

• Dislike needles
• Feel anxious about injections
• Prefer oral medication
• Travel frequently
• Want a tablet-based treatment

However, daily medication requires consistent adherence.

Mounjaro

Mounjaro is administered once weekly.

For someone who dislikes taking medication every day, a weekly injection may actually be easier to remember.

Therefore, the question is not simply whether tablets or injections are better.

It is which method fits your lifestyle and preferences while remaining medically appropriate.

Wegovy tablets vs Mounjaro dosage

The dosing schedules are also different.

The UK-authorised Wegovy tablet starts at 1.5 mg once daily and is gradually increased to 4 mg, 9 mg and then 25 mg, with a minimum of one month at each dose level.

Mounjaro is administered once weekly and is also started at a lower dose before being increased gradually according to the prescribed treatment plan.

Dose escalation is important because gastrointestinal side effects can occur with both medicines.

You should never increase the dose more quickly than instructed by your prescriber.

Wegovy pill vs injection: what is the difference?

The Wegovy tablet and Wegovy injection both contain semaglutide, but they are different formulations.

The most obvious difference is how they are administered.

Wegovy tablet: once daily.

Wegovy injection: once weekly.

The oral tablet offers an alternative for people who prefer not to inject themselves.

However, you should not assume that the tablet and injection are interchangeable simply because they contain the same active ingredient.

They have different formulations and dosing instructions.

Always follow the instructions provided by your prescriber.

Wegovy tablets vs Mounjaro side effects

Both medicines can cause gastrointestinal side effects.

Potential side effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort
• Bloating
• Indigestion
• Reduced appetite

These effects may be particularly noticeable when treatment begins or when the dose is increased.

In OASIS 4, gastrointestinal adverse events occurred in 74.0% of participants receiving oral semaglutide, compared with 42.2% receiving placebo.

In SURMOUNT-5, gastrointestinal adverse events were also the most common adverse events with both tirzepatide and semaglutide, with most described as mild to moderate and occurring primarily during dose escalation.

This does not mean that everyone will experience significant side effects.

Individual tolerance varies.

For a more detailed explanation, read our guide to weight loss injection side effects.

Which has fewer side effects: Mounjaro or Wegovy?

There is no universal answer.

Both medicines can cause gastrointestinal symptoms, and the severity varies between individuals.

One person may tolerate semaglutide particularly well, while another may find tirzepatide easier to tolerate.

Your medical history, other medicines, dose and rate of dose escalation can all influence your experience.

This is why a weight-loss medication should not be selected solely on the basis of online reviews or another person's experience.

Is the Wegovy tablet safer than Mounjaro?

It would be premature to say that the Wegovy tablet is universally safer than Mounjaro.

Both are prescription medicines with potential side effects, contraindications and precautions.

The appropriate treatment depends on the individual.

Before prescribing, a clinician should consider factors including:

• Your medical history
• Current medicines
• Existing health conditions
• BMI
• Previous weight-management treatments
• Treatment goals
• Potential contraindications
• Your ability to tolerate the medication

The aim should be to find a treatment with an appropriate balance between effectiveness, safety and tolerability.

Is Mounjaro stronger than Wegovy?

The word "stronger" can be misleading.

If by stronger you mean greater average weight loss, tirzepatide produced greater weight reduction than injectable semaglutide in SURMOUNT-5.

The difference was substantial: 20.2% versus 13.7% at 72 weeks.

However, this does not establish that tirzepatide is stronger than oral Wegovy.

The OASIS 4 trial found that oral semaglutide 25 mg produced a 13.6% estimated mean reduction in body weight at week 64 compared with 2.2% with placebo.

These studies cannot simply be placed side by side as though they were the same trial.

Which is better for appetite suppression?

Both medicines can significantly affect appetite.

Wegovy tablets may help you:

• Feel fuller after eating
• Experience less hunger
• Reduce food intake
• Reduce cravings

Mounjaro can also reduce appetite and increase satiety.

Because tirzepatide acts on both GIP and GLP-1 receptors, it may produce stronger average weight-loss effects than GLP-1-only treatment in some clinical comparisons.

However, your individual response matters more than the mechanism on paper.

The medicine that produces the best appetite control for one person may not do the same for another.

Which is better for long-term weight management?

Neither medication should be viewed simply as a short-term weight-loss solution.

Weight management is often a long-term process.

The aim is not merely to reach a target number on the scales but to establish a sustainable approach to maintaining improvements in weight and overall health.

This can involve:

• Appropriate medication
• Balanced nutrition
• Regular physical activity
• Adequate protein intake
• Behavioural strategies
• Sleep and routine
• Regular clinical monitoring

At SynovaMed, our clinically supervised weight-management service combines prescription treatment where appropriate with clinical assessment and ongoing support.

What happens when you stop Wegovy or Mounjaro?

Another important consideration is what happens after treatment.

Stopping a weight-management medicine can lead to increased appetite and weight regain in some people.

Research has demonstrated that substantial weight regain can occur after stopping GLP-1-based treatment.

This is why stopping treatment should be considered as part of a longer-term weight-management plan rather than simply stopping medication once a target weight is reached.

If you are considering coming off treatment, read our guide to what happens when you stop Mounjaro or Wegovy.

Can you switch from Wegovy tablets to Mounjaro?

Some patients may be able to switch between weight-management medicines.

However, this should only be done under the supervision of an appropriately qualified prescriber.

Do not take Wegovy and Mounjaro together or create your own switching schedule.

Your clinician may consider:

• Why you want to switch
• Your current dose
• How much weight you have lost
• Side effects
• Appetite control
• Your medical history
• Other medication
• Your treatment goals

A medication switch should therefore be an individual clinical decision.

What about Wegovy tablets vs Foundayo?

Wegovy tablets are not the only new oral weight-management option to arrive in the UK.

Foundayo, containing orforglipron, was authorised by the MHRA in August 2026 for weight management and type 2 diabetes. It is a once-daily oral GLP-1 receptor agonist.

Foundayo and oral Wegovy are different medicines.

Wegovy tablets contain semaglutide, while Foundayo contains orforglipron.

If you are interested in the growing range of oral weight-loss medicines available in the UK, our Foundayo UK guide explains how orforglipron works, who may be suitable and how it compares with other treatments.

What is the best weight loss medication in the UK?

There is no single best weight-loss medication for everyone.

The most appropriate treatment depends on your individual circumstances.

This may include:

• Your BMI
• Existing medical conditions
• Current medicines
• Previous treatment
• Weight-loss goals
• Appetite
• Lifestyle
• Side-effect tolerance
• Preference for tablets or injections

The newest medication is not automatically the best medication.

Likewise, the medicine that produces the greatest average weight loss in a clinical trial is not necessarily the best choice for every individual.

A personalised clinical assessment is therefore essential.

Wegovy tablets or Mounjaro: which should you choose?

If you strongly prefer not to use injections, the Wegovy tablet may be an attractive option.

If you prefer once-weekly treatment and are comfortable with an injection, Mounjaro may be preferable.

If your primary concern is average weight-loss efficacy, tirzepatide has demonstrated greater weight reduction than injectable semaglutide in the direct SURMOUNT-5 comparison.

But again, this is not the same as proving Mounjaro is better than the Wegovy tablet.

The oral Wegovy evidence comes from a separate placebo-controlled trial, where semaglutide 25 mg produced substantial weight loss.

Therefore, the best choice is ultimately the treatment that is clinically appropriate for you and that you can use safely and consistently as part of a longer-term weight-management plan.

Frequently Asked Questions

Is the Wegovy pill better than Mounjaro?

There is no direct clinical trial establishing that the Wegovy tablet is better or worse than Mounjaro. Oral semaglutide has demonstrated significant weight loss in clinical trials, while tirzepatide has produced greater average weight loss than injectable semaglutide in a direct comparison.

Is Mounjaro better than Wegovy?

Mounjaro produced greater average weight loss than injectable Wegovy in the SURMOUNT-5 trial. However, this should not be interpreted as proof that Mounjaro is better than the new Wegovy tablet because the tablet was not studied in that trial.

Which is better, Mounjaro or Wegovy for weight loss?

Both can be effective. Tirzepatide produced greater average weight loss than injectable semaglutide in SURMOUNT-5, but there is not yet a direct Mounjaro-versus-oral-Wegovy trial.

Is Wegovy now available as a tablet in the UK?

Yes. The MHRA approved oral Wegovy for weight loss and weight management in the UK on 11 June 2026.

Is the Wegovy tablet the same as the Wegovy injection?

Both contain semaglutide, but they are different formulations with different dosing schedules. The tablet is taken daily, while the traditional Wegovy injection is administered weekly.

Does the Wegovy tablet work for weight loss?

Yes. In the OASIS 4 clinical trial, oral semaglutide 25 mg produced an estimated mean weight reduction of 13.6% at week 64 compared with 2.2% with placebo.

Does Mounjaro cause more weight loss than Wegovy?

Mounjaro produced greater average weight loss than injectable semaglutide in the SURMOUNT-5 trial. It has not yet been directly compared with oral Wegovy in a head-to-head trial.

Which has more side effects, Mounjaro or Wegovy?

Both can cause gastrointestinal side effects including nausea, vomiting, diarrhoea and constipation. Individual tolerance varies, so neither can be considered universally better for side effects.

Can I switch from Wegovy tablets to Mounjaro?

A switch may be appropriate for some patients, but it should be planned and supervised by a qualified prescriber. Do not switch or combine prescription weight-loss medicines without medical advice.

Is Mounjaro stronger than the Wegovy pill?

Mounjaro has demonstrated greater average weight loss than injectable semaglutide in a direct clinical trial. However, there is insufficient direct evidence to say that it is stronger than oral Wegovy.

Which is better, a weight loss tablet or injection?

Neither is automatically better. A tablet may suit someone who dislikes injections, while a weekly injection may suit someone who prefers less frequent dosing. Effectiveness, safety, tolerability and individual circumstances should all be considered.

What happens if I stop Wegovy or Mounjaro?

Some people experience increased appetite and weight regain after stopping treatment. This is why stopping weight-loss medication should ideally be discussed with your prescriber and incorporated into a long-term weight-management plan.

Choosing the right weight-management treatment

The arrival of oral Wegovy gives eligible patients another option when considering prescription weight management.

For someone who does not want an injection, a daily semaglutide tablet may be particularly appealing.

For someone who prioritises weekly dosing and wants a treatment with strong evidence for substantial weight loss, tirzepatide may also be an option where clinically appropriate.

However, there is no universal winner.

Wegovy tablets and Mounjaro have not been directly compared in a head-to-head clinical trial.

What we do know is that oral semaglutide has demonstrated substantial weight loss compared with placebo, while tirzepatide has demonstrated greater average weight loss than injectable semaglutide in a direct trial.

The decision should therefore be based on your health, medical history, treatment goals, preferences and response to treatment.

At SynovaMed, prescription weight management begins with a clinical assessment rather than simply selecting a medication from a list. Eligible patients can explore the available weight loss treatments and receive clinician-led support throughout their treatment.

For a broader overview, see our guide to Mounjaro vs Wegovy, or learn more about weight loss injections in the UK.

Final verdict: Wegovy tablets vs Mounjaro

There is no proven overall winner between Wegovy tablets and Mounjaro.

Wegovy tablets offer the convenience of once-daily oral semaglutide, making them an appealing option for people who would prefer a tablet rather than an injection. Clinical research has shown significant weight loss with oral semaglutide 25 mg.

Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors. In a direct head-to-head trial, tirzepatide produced greater average weight loss than injectable semaglutide.

But that does not mean Mounjaro has been proven superior to the Wegovy tablet.

For now, the best treatment is the one that is clinically appropriate, safe, tolerable and realistic for your long-term weight-management goals.

Medical Disclaimer

This article is intended for general educational purposes and does not replace personalised medical advice, diagnosis or treatment. Wegovy and Mounjaro are prescription medicines and are not suitable for everyone. Treatment should only be started, stopped, changed or adjusted following advice from an appropriately qualified healthcare professional. Clinical-trial results represent average outcomes in specific study populations and should not be interpreted as a guarantee of individual weight loss.